WeVote
Log In

Bill

Bill

A 782

Revises licensure requirements for residential substance use disorders treatment facilities or programs.

2026-2027 Regular Session Introduced by Verlina Reynolds-Jackson and 2 co-sponsors

Bill A 782 modifies licensure standards for New Jersey residential substance use disorder treatment facilities to adjust regulatory requirements for program operations.

Reported and Referred to Assembly Health Infrastructure Committee
0
WeVote Research Nonpartisan
Bill Summary · A 782

Legislative bill overview

Bill A 782 revises the licensure requirements that residential substance use disorder (SUD) treatment facilities must meet to operate in New Jersey. The bill modifies existing regulatory standards for how these treatment programs are licensed and overseen. The specific changes to licensure requirements are not detailed in the available action history, but the bill directly impacts regulatory standards for addiction treatment facilities.

Why is this important

Licensure requirements directly affect treatment facility quality, safety standards, and access to care for individuals struggling with substance use disorders. Changes to these requirements can either lower barriers to treatment expansion or strengthen accountability measures. Given New Jersey's ongoing opioid crisis and treatment capacity needs, modifications to licensure could significantly influence the availability and consistency of SUD treatment options across the state.

Potential points of contention

  • Regulatory burden vs. accessibility: Relaxing requirements may expand treatment availability but could compromise quality standards; tightening them may ensure better care but could reduce facility capacity
  • Facility compliance costs: Changes may impose new operational or infrastructure expenses on existing programs, potentially affecting smaller or non-profit providers differently than large operators
  • Consumer protections and oversight: Modifications could shift the balance between operational flexibility for providers and regulatory oversight protecting vulnerable patients in treatment

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.